A randomized clinical trial study: Anti-oxidant, anti-hyperglycemic and anti-hyperlipidemic effects of olibanum gum in type 2 diabetic patients

Iranian Journal of Pharmaceutical Research

Volumn 13, Issue 3, 2014, Pages 1003-1010

  Azadmehr, Abbas ^a   Ziaee, Amir ^a   Ghanei, Laleh ^a   Huseini, Hassan Fallah ^b   Hajiaghaee, Reza ^b   Tavakoli Far, Bahareh ^c   Kordafshari, Gholamreza ^d  

^a QAZVIN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b AVICENNA RESEARCH INSTITUTE   (Iran)

^c ALBORZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes; Hyperglycemia; Hyperlipidemia; Olibanum gum resin; Patients

Indexed keywords

CHOLESTEROL; FLAVONOID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; OLIBANUM GUM; ORGANIC COMPOUND; PHENOL; PHENYLPROPANOID; PLACEBO; PLANT MEDICINAL PRODUCT; TERPENOID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIDIABETIC ACTIVITY; ANTIHYPERLIPIDEMIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; BOSWELLIA SERRATA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYTOCHEMISTRY; RANDOMIZED CONTROLLED TRIAL; THIN LAYER CHROMATOGRAPHY;

EID: 84905094281     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Campbell RK. Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies. J. Am. Pharm. Assoc. (2009) 49: 3-9.
2. Derosa G and Sibilla S. Optimizing combination treatment in the management of type 2 diabetes. Vasc. Health Risk Manag. (2007) 3: 665-671.
3. Krentz AJ and Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs (2005) 65: 385-411.
4. Fallah Huseini H, Kianbakht S, Hagiagaee R and Hashem Dabagian F. Anti- hyperglycemic and Anti-hypercholesterolemic Effects of Aloe vera Leaf Gel in Hyperlipidemic Type 2 Diabetic Patients: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Planta. Med. (2012) 78: 311-316.
5. Fallah Huseini H, Larijani B, Fakhrzadeh H, Radjabipour B, Toliat T and Reza M. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Phytother. Res. (2006) 20: 1036-1039.
6. Shojaii A, Goushegir A, Hashem Dabaghian F, Abdollahi Fard M and Fallah Huseini H. Herbs and herbal preparations for glycemic control in diabetes mellitus (a systematic review). J. Med. Plants Res. (2011) 5: 3846-3855.
7. Paranjpe P. Śallaki - Boswellia serrata: Indian Medicinal Plants - Forgotten Healers: A Guide to Ayurvedic Herbal MedicineChaukhamba Sanskrit Pratishthan Publishers, Delhi (2001) 233-234.
8. Aman U and Balu G. Pharmacological activities of Boswellia serrata Roxb-mini review Ethnobotanical. Leaflets (2009) 13: 766-774.
9. Ammon HPT. Boswellic acid in chronic inflammatory diseases. Planta/ Med. (2006) 72: 1100-1166.
10. Shen T and Lou H. Bioactive constituents of myrrh and frankincense, two simultaneously prescribed gum resins in Chinese traditional medicine. Chem. Biodiver. (2008) 5: 540-553.
11. Singh S, Khajuria A, Taneja SC, Khajuria RK, Singh J, Johri RK and Qazi GN. The gastric ulcer protective effect of boswellic acids, a leukotriene inhibitor from Boswellia serrata, in rats. Phytomed. (2008) 15: 408-415.
12. Siddiqui MZ. Boswellia serrata, a potential anti-inflammatory agent: an overview. Indian J. Pharm. Sci. (2011) 73: 255-261.
13. Ammon HP, Mack T, Singh GB and Safayhi H. Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of gum-resin exudates of Boswellia serrata. Planta Med. (1991) 57: 203-207.
14. Schweizer S, von Brocke AF, Boden SE, Bayer E, Ammon HP and Safayhi H. Workup-dependent formation of 5-lipoxygenase inhibitory boswellic acids analogues. J. Nat. Product. (2000) 63: 1058-1061.
15. Gayathri B, Manjula N, Vinaykumar KS, Lakshmi BS and Balakrishnan A. Pure compound from Boswellia serrata extract exhibits antiinflammatory property in human PBMCs and mouse macrophages through inhibition of TNF alpha, IL-1beta, NO and MAP kinases. Int. Immunopharmacol. (2007) 7: 473-482.
16. Arieh M and Raphael M. Boswellia resin: from religious ceremonies to medical uses: a review of in-vitro, in-vivo and clinical trials. J. Pharm. Pharmacol. (2010) 61: 1281-1293.
17. Murray MT. Rocklin, CA. Prima Publishing; The Healing Power of Herbs. (1995) 327-335.
18. Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta. Med. (2006) 72: 1100-1116.
19. Etzel R. Special extract of boswellia serrata (H15) in the treatment of rheumatoid arthritis. Phytomed. (1996) 3: 91-94.
20. Al-Awadi F, Fatania H and Shamte U. The effect of a plants mixture extract on liver gluconeogenesis in streptozocin induced diabetic rats. Diabetes Res. (1991) 18: 163-168.
21. Zutsi U, Rao PG and Kaur S. Mechanism of cholesterol lowering effect of Salai guggal ex-Boswellia serrata Roxb. Indian J. Pharmacol. (1986) 18: 182-183.
22. Rao AR, Veeresham C and Asres K. In-vitro and in-vivo inhibitory activities of four indian medicinal plant extracts and their major components on rat aldose reductase and generation of advanced glycation endproducts. Phytother. Res. (2013) 27: 753-760.
23. Shehata AM, Quintanilla-Fend L, Bettio S, Singh CB and Ammon HP. Prevention of multiple low-dose streptozotocin (MLD-STZ) diabetes in mice by an extract from gum resin of Boswellia serrata (BE). Phytomed. (2011) 18: 1037-1044.
24. Hossein Ashraf, Reza Heidari, Vahid Nejati and Minoo Ilkhanipoor. Effects of aqueous extract of Berberis integerrima root on some physiological parameters in streptozotocin-Induced diabetic rats. Iran. J. Pharm. Res. (2013) 12: 425-434.
25. Nouraddin Hosseinzadeh, Soodeh Seraj, Mohamad Ebrahim Bakhshi-Dezffoli, Mohammad Hasani, Mehdi Khoshneviszadeh, Saeed Fallah-Bonekohal, Mohammad Abdollahi, Alireza Foroumadi and Abbas Shafiee. Synthesis and antidiabetic evaluation of benzenesulfonamide derivatives. Iran. J. Pharm. Res. (2013) 12: 325-330.
26. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care (2003) 26: 21-24.
27. Kavitha JV, Rosario JF, Chandran J and Anbu P. Bakkiyanathan Hypoglycemic and other related effects of Boswellia glabra in alloxan-induced diabetic rats. Indian J. Physiol. Pharmacol. (2007) 51: 29-39.
28. Phillip K, Rambod D, Gckert PE, Walter E, M̈ller, Michael Karas, Manfred Schubert-Zsilavecz and Mona Abdel-Tawab. Metabolism of Boswellic Acids in-vitro and in-vivo. Drug Metab. Dispos. (200s8) 36: 1135-1142.
29. Gerlach U. Sorbitol dehydrogenase In: Bergmeyer, H.U. (ed.), Methods of enzymatic analysis. Third ed. Verlag Chemie, Weinheim. (1983) 112-117.